Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2008

Nerveda Picks Up Ore Pharmaceuticals’ Diagnostic Subsidiary

  • Nerveda has bought DioGenix from Ore Pharmaceuticals. The companies report that Ore is entitled to a small royalty on sales of a multiple sclerosis (MS) diagnostic.

    Nerveda will fund DioGenix with at least $5 million to accelerate and expand the company's programs. The most advanced are blood-based tests for the diagnosis and clinical management of MS.
     
    “The core diagnostic development assets of DioGenix coupled with the experience set of the management team provide a unique platform to develop a broad range of useful new tests,” says Cam Gallagher, president and CEO of Nerveda. “DioGenix neurological focus fits well with many of our projects, which target the development of new neuroprotective therapies.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »